Thyrocare Technologies Limited — Investor Meet, 28-07-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Thyrocare reported robust Q1 FY26 results: consolidated revenue jumped 23%, PAT surged 62%. Key growth drivers were a 20% rise in franchise revenue, 36% in partnerships, and a recovering PharmEasy business. The company processed 46.9 million tests (+15% YoY) and served 4.6 million patients (+12% YoY). Operational highlights include achieving 100% NABL accreditation, aiming for Six Sigma quality, and a 3.35-hour report turnaround time. Management, with a confident outlook, continues to expand its franchisee network (over 9,500 active) and focus on affordable, high-quality B2B diagnostics, reiterating mid-teen growth goals.